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Sexual health is defined by the World Health Organization as the integration of so-
matic, emotional, intellectual, and social aspects in ways that are positively enrich-
ing and that will enhance personality, communication, and love. The female sexual 
response is multifaceted and involves neurovascular, endocrine, and psychosocial 
factors. Optimal female sexual health comprises physical, mental, and emotional as-
pects, and these are the context in which a woman experiences desire, arousal, and 
orgasm. Sexual dysfunction in females is a complex and highly prevalent disease, 
and is commonly associated with the quality of life. Several factors influence female 
sexual function, including physiological and psychosocial factors. This article dis-
cusses models of female sexual response, defines and categorizes female sexual 
dysfunction, and identifies therapeutic modalities for female patients with sexual 
dysfunction.
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1. Introduction
Sexual health is defined by the World Health Organiza-
tion as the integration of somatic, emotional, intellec-
tual, and social aspects in ways that are positively 
enriching and that will enhance personality, communi-
cation, and love. The female sexual response is complex 
and is influenced by a multitude of factors including a 
complex interplay of physiological, psychological, and 
interpersonal components. Despite improved knowl-
edge of the female pelvic anatomy and recent under-
standing of the neurobiology and pharmacology of 
sexual responses, specifying a normal sexual response in 
women remains highly challenging and controversial. 
Traditionally, the female sexual response cycle was 
based on a linear model proposed by Masters and 
Johnson in the 1960s.1 This model proposed a succession 
through four phases of excitement, plateau, orgasm, and 
resolution, each of which has associated genital and ex-
tragenital responses. Despite the tremendous influence 
of the Masters and Johnson model, there are several 
limitations and criticisms.2 First, the model fails to ex-
plain the highly variable patterns of response seen from 
one woman to another or even the variability in re-
sponse from one episode to another in the same 
woman. Second, the model predominantly focuses only 
on the physiological aspects of the sexual response and 
does not reflect the importance of subjective, psycho-
logical, or interpersonal aspects of the sexual response. 
Finally, no indication is given of the importance of sexual 
desire or libido in their model.
To overcome these deficiencies, a three-phase model 
of the sexual response was proposed by Helen Singer 
Kaplan.3 According to this model, the sexual response 
cycle is conceptualized as including three essential phases: 
desire, excitement, and orgasm. The first phase of sexual 
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desire of Kaplan’s model consists of physiological and 
psychological components of sexual desire or libido, 
which are mediated by brain centers in the limbic sys-
tem but are also affected to a degree by hormonal (i.e., 
androgenic) and psychosocial factors. The desire phase 
is thought to be a necessary precursor to the develop-
ment of excitement and subsequent orgasm in men and 
women. Kaplan’s three-stage model was used as the 
basis of the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition, classification of female sexual 
dysfunction.4
More recently, in an attempt to reflect women’s true 
experiences of sexual responses, Basson proposed a cir-
cular model that incorporates psychological and social 
aspects into female sexual function, such as emotional 
intimacy and emotional satisfaction as well as sexual de-
sire and physical satisfaction.5 The model incorporates 
biological, psychological, and other factors in a more-
comprehensive framework. An important new concept 
in Basson’s model is that feelings of subjective arousal 
or emotional involvement do not always correlate with 
physiological measures of genital congestion. It is also 
possible for a woman to experience healthy sexual vaso-
congestion or genital lubrication with minimal or no 
feelings of sexual arousal or excitement. Other differ-
ences in Basson’s model from the traditional model of 
female sexual response are a discounting of the previ-
ously held notion regarding the primacy of spontaneous 
sexual desire in women and that orgasm and resolution 
are not essential in the sexual response cycle. These 
features set the current model apart from previous 
models of sexual response and may make it more reflec-
tive of women’s actual day-to-day sexual experiences. 
However, there are important limitations to this model 
that need to be recognized. First, it is largely based on 
clinical observations and lacks experimental verification. 
Moreover, the model is largely intimacy-based and may 
exclude some women whose sexual desires and arousal 
are not linked to intimacy. Nevertheless, by shifting the 
focus to include subjective and interpersonal factors and 
by recognizing the nonlinear nature of women’s sexual 
experiences, Basson’s model greatly contributes to the 
current understanding of a healthy sexual response in 
women.6
2.  Epidemiology of Female Sexual 
Dysfunction
In the most widely cited study based on the US National 
Health and Social Life Survey of 1992, which evaluated 
a sample of 1749 women aged 18–59 years, 43% re-
ported sexual dysfunction. Low libido was the most 
common complaint (51%) followed by problems with 
arousal (33%) and pain disorders (16%).7 Another inter-
national survey, including 4507 women aged 18–59 years, 
revealed that 34% of the participants had decreased 
sexual interest, and 19% did not consider sexual inter-
course to be pleasurable.8 Unfortunately, these data 
provide no information on prevalence rates in women 
over the age of 59 years or whether the sexual dysfunc-
tion was problematic or a cause of distress to the af-
fected individual. A survey from an older population of 
women (> 60 years) showed that two-thirds of the 448 
women were sexually inactive, 12% of married women 
had difficulty with intercourse, and approximately 14% 
experienced pain with intercourse.9 Whether a woman 
was sexually active was strongly correlated with her 
marital status. However, the study of older women 
lacked specific measures of female sexual dysfunction. 
A recent study including a female population up to age 
79 years reported sexual dysfunction in approximately 
35% of participants.10 In that study, 71% of women were 
sexually active, and 33% of the sexually active women 
were classified as having female sexual dysfunction by 
the answer of “somewhat of a problem” or “very much 
a problem” in at least one of the four domains studied, 
including a lack of interest, lack of enjoyment, difficulty 
in becoming aroused, and difficulty in having an orgasm. 
Although female sexual dysfunction is recognized as a 
highly prevalent health problem, some controversy ex-
ists regarding the prevalence of female sexual dysfunc-
tion. The epidemiology of female sexual dysfunction is 
still not well understood. This may be the result of varia-
tions in assessment techniques or the lack of standard-
ized definitions. 
3.  Definitions and Classification of Female 
Sexual Dysfunction
One of the major barriers to the advancement of re-
search on female sexual dysfunction is the absence of 
a well-defined diagnostic classification system. In 1998, 
The Sexual Function Health Council of the American 
Foundation for Urologic Disease convened an interdis-
ciplinary consensus conference panel consisting of 19 
experts on female sexual dysfunction selected from 
five countries. The purpose was to evaluate and revise 
the existing classifications and definitions of female sex-
ual dysfunction to include psychogenic and organically 
based disorders.11 An important component of the diag-
nostic system is the personal distress criterion, meaning 
that a condition is considered a disorder only if it causes 
distress for the woman experiencing the condition. The 
system uses the four major categories as described in 
the Diagnostic and Statistical Manual of Mental Disor-
ders, 4th edition, and the International Classification of 
Diseases, 10th Revision, but the definitions of several 
disorders were changed to reflect current clinical and 
research practice and a new category of sexual pain dis-
order was added (Table 1). This system was subse-
quently revised and further expanded, and is now 
widely accepted by healthcare providers and provides 
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guidelines for diagnosis and treatment.12–14 The classi-
fications can be subtyped as lifelong versus acquired, 
generalized versus situational, and organic versus psy-
chological or mixed.
4.  Sexual Desire Disorders
4.1.  Hypoactive sexual desire disorder (HSDD)
HSDD is a spectrum of diseases that causes personal 
distress owing to a persistent or recurring deficiency (or 
absence) of sexual fantasies and thoughts and a lack 
of receptivity to sexual activity.11–14 HSDD may result 
from psychological/emotional factors or be secondary to 
physiologic problems. Natural menopause, surgically or 
medically induced menopause, depression and its treat-
ments, and endocrine disorders are the most common 
causes that disrupt the normal female hormonal milieu, 
resulting in inhibited sexual desire.15,16 Long-term con-
flicting relationships have also been shown to adversely 
affect sexual desire.17
4.2.  Sexual aversion disorder
Sexual aversion disorder is a persistent or recurrent pho-
bic aversion leading to avoidance of sexual contact 
which causes personal distress.11–14 It is generally a psy-
chologically or emotionally based problem. It is often 
secondary to a history of physical or sexual abuse and 
childhood trauma.
4.3.  Sexual arousal disorder
Sexual arousal disorder is a persistent or recurring in-
ability to attain or maintain adequate sexual excitement 
causing personal distress.11–14 It may be experienced as 
a lack of subjective excitement, somatic responses, or 
genital lubrication/swelling. Sexual arousal disorder may 
be further subclassified as subjective, genital, or com-
bined. Subjective arousal disorder is characterized by 
absent or reduced feelings of sexual arousal, despite the 
occurrence of vaginal lubrication and genital swelling. 
Genital arousal disorder is characterized by a lack of vag-
inal lubrication or genital swelling, despite feelings of 
subjective arousal. Combined sexual arousal disorder is 
characterized by the absence of subjective arousal and 
genital arousal. Decreased labial and clitoral sensations 
and engorgement and lack of vaginal smooth muscle re-
laxation can also cause sexual arousal disorder. These con-
ditions may occur secondary to a medical/physiological 
basis such as diminished vaginal/clitoral blood flow, prior 
pelvic trauma, pelvic surgery, or medications. Psychological 
factors are among the other important causes of sexual 
arousal disorder.18 
4.4.  Orgasmic disorders
Orgasmic disorders are the persistent or recurrent dif-
ficulty in, delay in, or absence of attaining orgasm after 
sufficient sexual stimulation and arousal, which causes 
personal distress.11–14 Orgasmic disorders can be primary 
(a woman has never achieved orgasm) or secondary. 
Anorgasmia was observed in 24–37% of women present-
ing to sex therapy clinics for various reasons.19 Primary 
orgasmic disorder is usually due to emotional trauma or 
sexual abuse. Hormonal deficiency, surgical trauma, or 
medications are common causes for secondary orgasmic 
disorder. Anorgasmia is also a common complaint in 
women taking selective serotonin reuptake inhibitors.20
5.  Sexual Pain Disorders
5.1.  Dyspareunia
Dyspareunia is recurrent or persistent genital pain asso-
ciated with sexual intercourse.11–14 Dyspareunia can 
develop secondary to physiological or psychological dis-
orders such as vaginal atrophy, postmenopausal de-
creased vaginal lubrication, damage to the pelvic nerves 
as a complication of pelvic surgery, fear, anxiety, or inter-
personal conflict.21–23 
5.2.  Vaginismus
Vaginismus is recurrent or persistent involuntary spasms 
of the musculature of the outer third of the vagina that 
interferes with vaginal penetration and causes personal 
distress.11–14 Vaginismus usually develops as a condi-
tioned response to painful penetration, or secondary to 
psychological/emotional factors.24
5.3.  Other sexual pain disorders
Other sexual pain disorders include recurrent persistent 
genital pain induced by noncoital sexual stimulation.11–14 
This may include inflammatory or anatomic conditions, 
such as infections (i.e., herpes simplex virus), vestibulitis, 
prior genital mutilation or trauma, or endometriosis.24 
Table 1 Classification of female sexual dysfunction
I. Sexual desire disorders
 (1) Hypoactive sexual desire disorder
 (2) Sexual aversion disorder
II. Sexual arousal disorder
III. Orgasmic disorder
IV. Sexual pain disorders
 (1) Dyspareunia
 (2) Vaginismus
 (3) Noncoital sexual pain disorder
Based on the model by Basson et al.11
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6.  Assessment of Female Sexual Dysfunction
It is recommended that the evaluation of female sexual 
dysfunction involve an interview of the couple and each 
partner separately. The evaluation should include a de-
tailed medical and sexual history, with particular attention 
to potential psychiatric comorbidities, such as depres-
sion or anxiety, and a physical examination, including a 
gynecologic examination. Furthermore, a validated self-
assessment questionnaire is practical, efficient, objec-
tive, and inexpensive, providing a very useful tool for 
research and clinical practice. In addition, the history 
should focus on the duration of the disorder (primary or 
secondary) and the psychosocial factors involved, such 
as any recent life changes or stressors. There are several 
validated self-assessment questionnaires available to 
evaluate female sexual function (Table 2),25–29 such as 
the Female Sexual Function Index (FSFI, available at www.
fsfi-questionnaire.com).27 The FSFI, which has been trans-
lated into Chinese, is a 19-item questionnaire that charac-
terizes six domains of sexual function. More specifically, 
Q1 and Q2 are grouped into the desire domain, Q3–Q6 are 
grouped into the arousal domain, Q7–Q10 are grouped 
into the lubrication domain, Q11–Q13 are grouped into 
the orgasm domain, Q14–Q16 are grouped into the satis-
faction domain, and Q17–Q19 are grouped into the pain 
domain (Table 3). The full FSFI scores range from 2–36. 
A woman with a total FSFI score of ≤ 26 is considered to 
be at risk of sexual dysfunction. These questionnaires 
can also be used to monitor response to treatment.
Routine laboratory testing is not recommended un-
less a hormonal deficiency is suspected. Dehydroepian-
drosterone sulfate reflects adrenal androgen secretion 
and may highlight an adrenal insufficiency.30 Thyroid-
stimulating hormone may identify a thyroid dysfunction. 
Measurement of sex steroid levels, such as estrogen and 
testosterone, is seldom useful.31–33 Specialized diagnostic 
tools such as duplex Doppler ultrasonography, vaginal 
pH measurements, and vaginal/clitoral sensory perception 
thresholds are not widely available and require expen-
sive equipment.34 Although useful for study purposes, 
this equipment is not essential to evaluate and diagnose 
patients with sexual dysfunction.
7.  Management of Female Sexual 
Dysfunction
The female sexual response is multifaceted and involves 
neurovascular, endocrine, and psychosocial factors. 
Optimal female sexual health comprises physical, men-
tal, and emotional aspects, and these are the context in 
which a woman experiences desire, arousal, and orgasm. 
Table 4 shows treatments for female sexual dysfunction. 
A psychosocial intervention may be necessary based on 
the woman’s relationships, current life stressors, and sex-
ual problems. An open discussion should take place with 
the patient and her partner. It is important to educate 
the patient and partner about the diagnosis and physio-
logical basis of female sexual dysfunction, and to estab-
lish goals and expectations of treatment. Patients should 
be educated that not having orgasms with each sexual 
encounter does not mean that the experience was a fail-
ure, and clitoral stimulation may be more likely to lead to 
orgasm than coital intercourse.35 Modifications of life-
style, such as changing to a healthy diet, reducing stress 
factors, participating in regular physical activities, elimi-
nating risk factors (smoking, drinking, illicit drug use, and 
obesity), and optimally treating medical diseases that 
can affect female sexual dysfunction such as hyperten-
sion, hyperlipidemia, and diabetes are also part of the 
Table 2  Questionnaires for evaluating female sexual 
dysfunction
Questionnaire
 No. of Characterization of
 items domains
Brief index of 22 Three domains
sexual functioning    (1) interest/desire
for women    (2) activity
    (3) satisfaction
Short scale of  9 Four domains
McCoy female    (1) desire
sexuality    (2) arousal
questionnaire    (3) orgasm
    (4) dyspareunia
Female sexual 19 Six domains
function index    (1) desire
    (2) arousal
    (3) lubrication
    (4) orgasm
    (5) satisfaction
    (6) pain
Changes in sexual 36 Five domains
functioning    (1) pleasure
questionnaire    (2) frequency
    (3) desire
    (4) arousal
    (5) orgasm
Multidimensional 61 Twelve domains
sexuality    (1) sexual-esteem
questionnaire    (2) sexual-preoccupation
    (3) internal-sexual-control
    (4) sexual-consciousness
    (5) sexual-motivation
    (6) sexual-anxiety
    (7) sexual-assertiveness
    (8) sexual-depression
    (9) external-sexual-control
   (10) sexual-monitoring
   (11) fear-of-sex
   (12) sexual-satisfaction
Female sexual dysfunction
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management.30,36 The woman and her partner need to 
improve communication and reduce strains on the rela-
tionship when present because a strong impetus for 
female sexuality is intimacy.30
The study of female sexual dysfunction has lagged 
behind research into male sexual health, resulting in 
very slow progress in developing pharmacological thera-
pies for female sexual dysfunction. Hormonal treatment, 
primarily with estrogen and testosterone, is one of the 
mainstays of treatment for some types of female sexual 
dysfunction. Estrogen is important in maintaining ade-
quate lubrication and preventing atrophy of vaginal and 
vulvar tissues, with many complaints of dyspareunia in 
menopause correlated to the decreased estrogen levels. 
However, studies have documented that systemic estro-
gen alone is insufficient to cure symptoms of sexual dys-
function.37,38 Additionally, estrogen treatment increases 
sex hormone-binding globulin levels and depletes levels 
of bioavailable testosterone, potentially exacerbating 
androgen insufficiency. Therefore, estrogen therapy, 
often applied topically, is commonly used for dyspareu-
nia.39 A review of earlier studies on the use of testoster-
one in postmenopausal women for low libido concluded 
that there are benefits in terms of improved sexual func-
tion with the addition of testosterone to standard post-
menopausal hormone therapy.40 Subsequent large, 
randomized control trials in both surgically menopau-
sal41–43 and naturally menopausal women44 demon-
strated that treatment with the addition of testosterone 
resulted in significant improvements in desire, arousal, 
responsiveness, orgasm, pleasure, and satisfaction when 
compared with a placebo. However, the role of andro-
gens in treating female sexual dysfunction is still contro-
versial because there is no information on long-term 
testosterone use and no established normal levels for 
testosterone or free testosterone in women. Furthermore, 
few assays can provide the necessary sensitivity and spe-
cificity to recommend widespread use of lab measure-
ments.45 Studies of phosphodiesterase type-5 inhibitors, 
dopaminergic agonists, and prostaglandins have not pro-
vided evidence of a significant benefit for female sexual 
dysfunction.46,47
In summary, women with sexual dysfunction may 
have problems that overlap with different stages of sexual 
function, arousal, desire, orgasm, or pain. Manage ment 
of female sexual dysfunction largely depends on the etiol-
ogy. A collaborative and comprehensive evaluation, pa-
tient and partner education, and behavioral modifications, 
followed by individualized pharmacotherapy in selected 
patients should be the standard management of women 
with sexual dysfunction.
Table 4 Treatment for female sexual dysfunction
Psychosocial treatments
 Psychoeducation
 Sensate focus
 Cognitive restructuring
 Communication training
 Self and/or partner exploration
 Sexual fantasy training
 Directed masturbation
Medical treatments
 Estrogen
 Testosterone
 Others (PDE5 inhibitors, dopaminergic agonists, and 
  prostaglandins)
PDE5 = phosphodiesterase type 5.
Table 3  Questions on the Female Sexual Function Index 
(FSFI)
Over the past 4 weeks
 Q1 How often did you feel sexual desire or interest?
 Q2 How would you rate your level (degree) of sexual 
desire or interest?
 Q3 How often did you feel sexually aroused (“turned 
on”) during sexual activity or intercourse?
 Q4 How would you rate your level of sexual arousal 
(“turn on”) during sexual activity or intercourse?
 Q5 How confident were you about becoming sexually 
aroused during sexual activity or intercourse?
 Q6 How often have you been satisfied with your arousal 
(excitement) during sexual activity or intercourse?
 Q7 How often did you become lubricated (“wet”) during 
sexual activity or intercourse?
 Q8 How difficult was it to become lubricated (“wet”) 
during sexual activity or intercourse?
 Q9 How often did you maintain your lubrication 
(“wetness”) until completion of sexual activity or 
intercourse?
Q10 How difficult was it to maintain your lubrication 
(“wetness”) until completion of sexual activity or 
intercourse?
Q11 When you had sexual stimulation or intercourse, 
how often did you reach orgasm (climax)?
Q12 When you had sexual stimulation or intercourse, 
how difficult was it for you to reach orgasm (climax)?
Q13 How satisfied were you with your ability to reach 
orgasm (climax) during sexual activity or intercourse?
Q14 How satisfied have you been with the amount of 
emotional closeness during sexual activity between 
you and your partner?
Q15 How satisfied have you been with your sexual 
relationship with your partner?
Q16 How satisfied have you been with your overall 
sexual life?
Q17 How often did you experience discomfort or pain 
during vaginal penetration?
Q18 How often did you experience discomfort or pain 
following vaginal penetration?
Q19 How would you rate your level (degree) of discomfort 
or pain during or following vaginal penetration?
T.F. Tsai, et al
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8.  Conclusions
Female sexual dysfunction is a complex and highly prev-
alent disease that affects a large number of women. 
Several factors influence female sexual function, includ-
ing physiological and psychosocial factors. Assessment 
of female sexual dysfunction should include a complete 
medical and psychosocial history, and a physical exami-
nation. Routine laboratory testing is not recommended 
unless a hormonal deficiency is suspected. Treatment 
should be multidisciplinary and depends on the etiology 
of female sexual dysfunction. Further research in this 
area should attempt to better understand the physiol-
ogy of female sexuality and to create (pharmacological 
and non-pharmacological) treatment algorithms suita-
ble for female sexual dysfunction.
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